Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/27325
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorVermersch, P.-
dc.contributor.authorBoyko, A.-
dc.contributor.authorde Seze, J.-
dc.contributor.authorHartung, H. -P.-
dc.contributor.authorHavrdova, E. Kubala-
dc.contributor.authorInshasi, J. Said-
dc.contributor.authorMcCombe, P.-
dc.contributor.authorMontalban, X.-
dc.contributor.authorPozzili, C.-
dc.contributor.authorMelanson, M.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorRodriguez, C.-
dc.contributor.authorSelmaj, K.-
dc.date.accessioned2018-11-12T14:18:21Z-
dc.date.available2018-11-12T14:18:21Z-
dc.date.issued2018-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 24-25-
dc.identifier.issn1351-5101-
dc.identifier.urihttp://hdl.handle.net/1942/27325-
dc.description.sponsorshipSanofi; Bayer HealthCare Pharmaceuticals-
dc.language.isoen-
dc.publisherWILEY-
dc.titleAlemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 16-19, 2018-
local.bibliographicCitation.conferencename4th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceLisbon, PORTUGAL-
dc.identifier.epage25-
dc.identifier.issueS2-
dc.identifier.spage24-
dc.identifier.volume25-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium. [Vermersch, P.] Univ Lille, Lille, France. [Boyko, A.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [de Seze, J.] Univ Strasbourg, Strasbourg, France. [Hartung, H. -P.] Heinrich Heine Univ, Dusseldorf, Germany. [Havrdova, E. Kubala] Charles Univ Prague, Fac Med 1, Prague, Czech Republic. [Inshasi, J. Said] Rashid Hosp, Dubai, U Arab Emirates. [Inshasi, J. Said] Dubai Med Coll, Dubai, U Arab Emirates. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Montalban, X.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada. [Montalban, X.] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain. [Pozzili, C.] Sapienza Univ Rome, Rome, Italy. [Melanson, M.; Daizadeh, N.; Rodriguez, C.] Sanofi, Cambridge, MA USA. [Selmaj, K.] Med Univ Lodz, Lodz, Poland.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000435272000041-
item.fulltextNo Fulltext-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorVermersch, P.-
item.contributorBoyko, A.-
item.contributorde Seze, J.-
item.contributorHartung, H. -P.-
item.contributorHavrdova, E. Kubala-
item.contributorInshasi, J. Said-
item.contributorMcCombe, P.-
item.contributorMontalban, X.-
item.contributorPozzili, C.-
item.contributorMelanson, M.-
item.contributorDaizadeh, N.-
item.contributorRodriguez, C.-
item.contributorSelmaj, K.-
item.fullcitationVAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C. & Selmaj, K. (2018) Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study). In: EUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 24-25.-
item.accessRightsClosed Access-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.